Teprotumumab shows promise in thyroid eye disease regardless of disease duration

Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), has shown significant promise in treating thyroid eye disease (TED) regardless of the duration of the disease or the presence of active inflammation markers within the orbit, according to a recent review.

Teprotumumab, initially approved for patients with recent-onset TED, has also demonstrated effectiveness in cases where prior interventions had failed or in treatment-naïve patients with stable, long-standing TED.

The authors of the review said that treatment with teprotumumab has led to notable improvements in clinical signs and symptoms, such as proptosis and diplopia, and has shown reductions in pathologic orbital changes according to orbital imaging assessments.

Reference
Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol. 2023;doi: 10.1097/ICU.0000000000000997. Epub ahead of print. PMID: 37610428.